{
    "pmcid": "10532743",
    "qa_pairs": {
        "How might VNARs serve as a broad-spectrum antiviral strategy against future coronavirus outbreaks?": [
            "By binding to conserved regions of the spike protein.",
            "By rapidly mutating to match new virus strains.",
            "By increasing the immune response to unrelated viruses.",
            "By targeting the virus's RNA directly."
        ],
        "What advantage do VNARs have over traditional monoclonal antibodies in terms of stability?": [
            "VNARs maintain stability under extreme thermal and chemical conditions.",
            "VNARs are more susceptible to degradation in high-temperature environments.",
            "VNARs require refrigeration to maintain their stability.",
            "VNARs lose stability when exposed to chemical agents."
        ],
        "What method is used to isolate VNARs that bind to the SARS-CoV-2 spike protein?": [
            "Phage display technology.",
            "CRISPR-Cas9 gene editing.",
            "Polymerase chain reaction (PCR).",
            "X-ray crystallography."
        ],
        "What unique property of VNARs allows them to target the SARS-CoV-2 spike protein's receptor-binding domain effectively?": [
            "Their ability to bind to distinct epitopes inaccessible to conventional antibodies.",
            "Their larger size compared to traditional antibodies.",
            "Their ability to change shape to fit different epitopes.",
            "Their reliance on a secondary binding protein for stability."
        ],
        "Why is humanization necessary for VNARs when used in humans?": [
            "To reduce potential immunogenicity while retaining binding properties.",
            "To increase their size for better efficacy.",
            "To enhance their ability to bind to non-human targets.",
            "To improve their chemical stability in human tissues."
        ]
    }
}